TOP HEADLINES

Featured Story

Computer modeling could help design next-generation antibiotics

A team at the University of Bristol in the U.K. used computer simulations to gain insight into how drug-resistant bacteria are able to ward off antibiotics.

Protein boost restores hearing in deaf mice

Zeroing in on a protein that's vital to providing communication between the ears and brain, scientists have restored hearing in mice that were partly deaf. The researchers say that boosting the production of this protein in humans through gene therapy may be able to one day cure people who have lost part or all of their hearing.

GlaxoSmithKline drug flips off cancer mechanism in aggressive leukemia

Turning off an enzyme switch that is needed to activate tumor growth may be an effective way to combat an aggressive kind of cancer called T-cell acute lymphoblastic leukemia, according to researchers at New York University's Langone Medical Center.

Researchers pinpoint potent anti-obesity compounds

Researchers from the National University of Singapore have identified several potent inhibitors that selectively target FTO, a gene that has been associated with fat mass and obesity in certain people.

Human intestinal organoids grown in mice could help personalize treatments

Researchers have grown human intestinal tissue from pluripotent stem cells and transplanted the living tissue into mice. These so-called organoids could provide a more accurate model for testing drugs designed to work on the intestines as well as help generate intestinal tissue for new treatments.

MORE NEWS

From Our Sister Sites

FierceVaccines

To help show Americans just how important its flu vaccines are, Novartis has teamed up with entertainer Nick Cannon, who's advising consumers to prepare for flu season by getting their shots and stocking up on the Swiss pharma's over-the-counter remedy, Theraflu.

FierceVaccines

GlaxoSmithKline's vaccines unit will be getting a new look come next year, when it's expected to absorb the bulk of Novartis' vaccines lineup it bought for $7.1 billion back in April. It'll have some new management, too, with Moncef Slaoui in the chairman's role. And judging from the pharma giant's Q3 results, some change for the unit could be a good thing.